Why Patients Drop Off GLP-1 Treatment — And How to Keep Them

GLP-1 receptor agonists are among the most effective weight management treatments ever developed. Yet real-world data tells a sobering story: a large proportion of patients who start treatment do not continue it. For prescribers — whether in pharmacy, general practice, online services, or specialist clinics — understanding why patients drop off is the first step towards fixing it.

The adherence problem in numbers

The gap between clinical trial retention and real-world persistence is stark. In the STEP and SURMOUNT trials, retention rates exceeded 85% at 68–72 weeks — but participants had regular contact with clinical teams and structured follow-ups.

Real-world data paints a different picture. A 2023 study published in Obesity found that fewer than 50% of patients prescribed semaglutide for weight management remained on treatment at 12 months. A separate analysis of pharmacy claims data showed that roughly one-third discontinued within the first 90 days. The problem is not unique to any one setting — it affects community pharmacies, online prescribers, private GPs, and specialist clinics alike.

The weeks 2–3 danger zone

The highest-risk period for dropout is earlier than most prescribers realise. Weeks two and three of treatment — and the first fortnight after any dose escalation — represent a critical vulnerability window.

This is when side effects peak. Nausea tends to be most intense during the first two to four weeks at each dose level, correlating with rising plasma concentrations as the drug approaches steady state. For a patient who has just started treatment, this can feel overwhelming — particularly if they were not adequately prepared.

The danger is compounded by the fact that meaningful weight loss has usually not yet occurred. Patients experience the worst side effects with little visible reward. The rational calculation becomes simple: stop.

Why patients leave: the key drivers

1. Unmanaged side effects

Nausea, vomiting, constipation, and diarrhoea are expected pharmacological effects — but “expected” does not mean “tolerable” without support. Patients who lack clear, practical guidance on managing side effects are far more likely to discontinue. The problem is often not the severity itself, but the absence of reassurance when it occurs.

2. Unrealistic expectations

Many patients arrive with expectations shaped by social media and headline weight loss figures. When they do not lose a stone in the first fortnight, frustration sets in. Equally, patients who experience an initial rapid loss often hit a plateau at weeks 8–12 and interpret it as treatment failure rather than a normal physiological response.

Setting realistic expectations at the point of prescribing — and reinforcing them throughout treatment — is essential.

3. The weight loss plateau

Even well-informed patients find plateaus psychologically difficult. After weeks of visible progress, a period of stable weight at weeks 8–12 can feel demoralising. Without proactive support, motivation erodes. Patients start skipping doses, reduce their engagement, and eventually stop altogether.

4. Cost burden

GLP-1 receptor agonists are not inexpensive, particularly in private prescribing settings. Patients paying out of pocket face a cumulative cost that becomes harder to justify during slow periods or when side effects are troublesome. Transparent conversations about treatment duration and long-term cost help patients make informed decisions rather than impulsive ones.

5. Isolation between appointments

Perhaps the most underappreciated driver of dropout is the gap between clinical contacts. A patient who injects on Monday, feels nauseated on Tuesday, and has no scheduled contact for four weeks is effectively unsupported during the most critical period of their treatment cycle.

In clinical trials, participants had frequent touchpoints with research teams. In real-world prescribing, patients often have a consultation at initiation and then minimal contact until they quietly stop collecting their prescription.

What structured support looks like

The evidence consistently shows that more frequent patient contact improves adherence. A 2024 analysis in The Lancet Digital Health found that digital health interventions with regular engagement reduced discontinuation by 25–35% compared to standard care.

Structured support does not mean more clinic time. It means the right information, at the right time, delivered in a way that scales. In practice, this looks like:

• Daily check-ins that take patients less than a minute to complete, capturing symptoms, adherence, and mood
• Automated flagging that alerts prescribers when a patient reports worsening symptoms or missed doses — before the patient disengages entirely
• PK-informed timing that anticipates when side effects are most likely based on the dosing cycle, allowing proactive rather than reactive support
• Visible progress tracking that helps patients see trends beyond the daily number on the scales

This is exactly what Cadence provides. The platform was designed specifically for GLP-1 prescribers who need to support patients between appointments without multiplying their workload. The prescriber dashboard surfaces the patients who need attention, so clinical time goes where it matters most.

Retention is a clinical outcome

It is easy to view adherence as a patient responsibility. But retention is shaped by the support infrastructure around the prescription. The same drug, given to the same patient, produces different outcomes depending on how well that patient is supported through side effects, plateaus, and uncertainty.

For prescribers who want to improve retention — across pharmacy, clinic, or online settings — the starting point is recognising that the prescription is the beginning of treatment, not the end of it.

Book a demo to see how Cadence helps prescribers keep patients on track throughout their GLP-1 journey.